Novo Nordisk Partners with Anthropic to Speed Up Drug Development

Novo Nordisk, maker of Ozempic, has partnered with Anthropic to use Claude Science to accelerate drug development, while Polymarket puts the odds of FDA approving Eli Lilly's Retatrutide this year at just 3%.

2026-09-16 ~ 2026-09-16 · 2 related posts

• Ozempic maker Novo Nordisk partners with Anthropic's Claude Science for drug development — Polymarket · 2026-09-16
• Novo Nordisk partners with Anthropic to speed drug development using Claude Science — Polymarket · 2026-09-16